Φορτώνει......
Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis
BACKGROUND: Budesonide multimatrix (MMX) system has been approved for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), and offers potential safety benefits over more commonly utilized corticosteroid therapies. OBJECTIVES: In a real-world setting we aimed...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Inflamm Intest Dis |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
S. Karger AG
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6751477/ https://ncbi.nlm.nih.gov/pubmed/31559263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000501004 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|